JIANGXI BIO Announced 2026 Interim Results
Overseas Contract Orders Reach Nearly RMB27.4 mn and R&D Translation Gains Momentum, with the AEPC Platform Reshaping the R&D Paradigm for Equine Polyclonal Antibody Interim Results Highlights Key Financial Indicators Revenue amounted to...